Clofoctol

Clofoctol
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Rectal (suppository)[1]
ATC code	J01XX03 (WHO) ;
Pharmacokinetic data
Bioavailability	98%[1]
Metabolism	Hepatic glucuronidation[1]
Excretion	Biliary[1]
Identifiers
	IUPAC name 2-[(2,4-dichlorophenyl)methyl]-; 4-(2,4,4-trimethylpentan-2-yl)phenol;
CAS Number	37693-01-9 ;
PubChem CID	2799;
ChemSpider	2697 ;
UNII	704083NI0R;
KEGG	D07244 ;
ChEMBL	ChEMBL1476605;
CompTox Dashboard (EPA)	DTXSID5045889 ;
ECHA InfoCard	100.048.739
Chemical and physical data
Formula	C21H26Cl2O
Molar mass	365.34 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1cc(Cl)ccc1Cc2cc(ccc2O)C(C)(C)CC(C)(C)C;
	InChI InChI=1S/C21H26Cl2O/c1-20(2,3)13-21(4,5)16-7-9-19(24)15(11-16)10-14-6-8-17(22)12-18(14)23/h6-9,11-12,24H,10,13H2,1-5H3 ; Key:HQVZOORKDNCGCK-UHFFFAOYSA-N ;
	(verify)

Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria.[1] It has been marketed in France till 2005 under the trade name Octofene and in Italy as Gramplus.

It is only functional against Gram-positive bacteria.[2]

It penetrates into human lung tissue.[3]

According to the press agency AEF info, the Pasteur Institute of Lille is developing clofoctol as a potential therapy against SARS-CoV-2.[4]

On April 19, 2020, the Beauty, Biology and Philosophy website had proposed to use clofoctol for a therapy intended for people who preferentially express the TAS2R38 bitterness receptor, these same people being those who are most predisposed to severe forms of SARS-CoV-2.[5]

References

"Gramplus" (in Italian). Studio Medico Torrino. July 25, 2007. Archived from the original on March 8, 2016. Retrieved 2007-08-10.
Combe J, Simonnet F, Yablonsky F, Simonnet G (1980). "[Clofoctol binding by the bacteria (author's transl)]". J Pharmacol (in French). 11 (4): 411–25. PMID 6782374.
Danesi R, Gasperini M, Senesi S, Freer G, Angeletti CA, Del Tacca M (1988). "A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay". Drugs Exp Clin Res. 14 (1): 39–43. PMID 3391105.
"Pasteur Lille obtient 5 M€ de LVMH pour repositionner un ancien médicament, l'Octofene, sur le traitement du Covid" (in French). AEF info. October 13, 2020. Retrieved 2020-10-13.
"Goûter. L'amertume pour soigner ... les Brocoli-Beurk ?" (in French). April 19, 2020.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Gramplus-1] "Gramplus" (in Italian). Studio Medico Torrino. July 25, 2007. Archived from the original on March 8, 2016. Retrieved 2007-08-10.

[pmid6782374-2] Combe J, Simonnet F, Yablonsky F, Simonnet G (1980). "[Clofoctol binding by the bacteria (author's transl)]". J Pharmacol (in French). 11 (4): 411–25. PMID 6782374.

[pmid3391105-3] Danesi R, Gasperini M, Senesi S, Freer G, Angeletti CA, Del Tacca M (1988). "A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay". Drugs Exp Clin Res. 14 (1): 39–43. PMID 3391105.

[4] "Pasteur Lille obtient 5 M€ de LVMH pour repositionner un ancien médicament, l'Octofene, sur le traitement du Covid" (in French). AEF info. October 13, 2020. Retrieved 2020-10-13.

[5] "Goûter. L'amertume pour soigner ... les Brocoli-Beurk ?" (in French). April 19, 2020.